ClinicalTrials.gg
CompletedNCT04316143Updated Oct 15, 2024Results posted

Pharmacokinetics, Safety and Efficacy of BIA 5-1058 in PAH (Zamicastat)

A Phase 2 interventional study of Oral zamicastat in Pulmonary Arterial Hypertension, sponsored by Bial - Portela C S.A.. Completed at 13 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Bial - Portela C S.A. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2019, registered Mar 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing zamicastat in Pulmonary Arterial Hypertension — none open to participants now, none under way, none of them phase 3. zamicastat · Pulmonary Arterial Hypertension.

Enrollment
7th of 11
33 · median 44
Started
2019
with 1 other
Phase 2
2 of 11
none open now
Registered
3rd of 11
by date
Lead sponsor
11 of 11
Bial - Portela C S.A.

Among the 11 studies testing zamicastat in Pulmonary Arterial Hypertension, this one is the 7th largest by enrollment, is one of 2 that started in 2019, is one of 2 in phase 2, and was the 3rd registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

None of the 11 studies testing zamicastat in Pulmonary Arterial Hypertension is open now. The open studies under Pulmonary Arterial Hypertension, anywhere →

About zamicastat

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing zamicastat in Pulmonary Arterial Hypertension as a file.
02

Study summary

This Study evaluates the pharmacokinetic (PK) profile of different zamicastat doses in Pulmonary arterial hypertension (PAH) patients to find the most promising therapeutic dosage range for the treatment of PAH disease

Read the detailed description

This is an open-label, multi-centre study in patients with PAH who are currently on stable treatment with at least one PAH medication. It is planned to evaluate the PK profile (24 hour profile and trough levels) and the safety, tolerability and efficacy of four different zamicastat doses. Each patient will start treatment with the lowest dose (50 mg zamicastat once daily) and the dose will be up-titrated to the individual highest tolerated dose (HTD) i.e. up to 200 mg zamicastat once daily.

A data safety monitoring board (DSMB) will periodically review the safety data and will issue a recommendation if the doses can be used as planned.

This study will consist of:

  • A screening period, 5 to 12 days: visit V1
  • Up to four dose finding periods, 14 days each:

    • Dose A (50 mg zamicastat once daily): visits A1, A2 and A3
    • Dose B (100 mg zamicastat once daily): visits B2 and B3
    • Dose C (150 mg zamicastat once daily): visits C2 and C3
    • Dose D (200 mg zamicastat once daily): visits D2 and D3
  • Maintenance period, 42 days: maintenance period visit (MPV)1, MPV2 and MPV3
  • Follow-up (FU) period, 14 to 28 days: visits FU (down-titration) and FU
03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • PAH
  • BIA 5-1058
  • Zamicastat
  • Bial
  • Bial - Portela & Ca, S.A.
  • dopamine ß-hydroxylase (DßH) inhibitor
  • vascular obstruction
  • pulmonary arteries
  • right-heart catheterisation (RHC)
  • idiopathic
  • rare lung disease
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged 18 to 70 years.
  2. Able to comprehend and willing to sign an form.
  3. Diagnosis of PAH (pulmonary arterial hypertension WHO Group 1), documented by right heart catheterisation with a mean pulmonary artery pressure (mPAP) ≥ 25 mmHg, a pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg and a pulmonary vascular resistance (PVR) > 3 wood unit (WU):

    1. Idiopathic, in non-vasoreactive patients
    2. Heritable: Bone morphogenetic protein receptor type II (BMPR2) mutation and other mutations, in non-vasoreactive patients
    3. Drugs and toxin induced, in non-vasoreactive patients
    4. Associated with connective tissue disease
    5. Associated with simple congenital defects (atrial septal defect and/or ventricular septal defect) if closed > 12 months before inclusion.
  4. World Health Organization (WHO) functional class II or III as judged by the investigator.
  5. Stable treatment with at least one of the following approved PAH therapies for at least 90 days prior to V1: Ambrisentan, Bosentan, Macitentan, Riociguat, Selexipag, Sildenafil, Tadalafil, Epoprostenol intravenous, Iloprost inhaled or Treprostinil intravenous or subcutaneous.

Exclusion criteria

Exclusion Criteria:

  1. to zamicastat, i.e. known to ingredients of zamicastat formulation.
  2. Two or more consecutive measurements of systolic blood pressure (SBP) \< 95 mmHg or diastolic blood pressure (DBP) \< 50 mmHg.
  3. Uncontrolled diabetes mellitus with ≥ 8.5% within the last three months or at screening.
  4. PAH WHO Group 1 due to portal hypertension, (HIV) infection and schistosomiasis.
  5. Any disease known to cause pulmonary hypertension other than PAH WHO Group 1.
  6. Obstructive lung disease: /Forced Vital Capacity (FEV1/FVC) \< 60% and FEV1 \< 60% of predicted value after bronchodilator administration.
  7. Restrictive lung disease: Total Lung Capacity (TLC) \< 70% of predicted value.
  8. History of moderate to severe hepatic impairment ( B and C).
  9. Estimated (eGFR) \< 30 mL/min/1.73 m2 (measured at V1).
  10. Use of the following prohibited medication or treatments during study participation: calcium channel blockers (CCBs) if used for the treatment of PAH in vasoreactive patients; drugs containing a catechol group that is metabolised by dopamine ß-hydroxylase (DβH) e.g. rimiterole, isoprenaline, dopamine, dopexamine or dobutamide or α- and/or β-blockers.
  11. Current or previous (within the past year) alcohol or substance abuse excluding caffeine or nicotine.
  12. Presence of any other significant or progressive/unstable medical condition that, in the opinion of the investigator, would compromise evaluation of the study treatment or may jeopardise the patient's safety, compliance or adherence to protocol requirements.
  13. For women: Pregnancy or breast-feeding. Women of unable or unwilling to undergo pregnancy tests and practice acceptable measures from the time of until 30 days after last medicinal product (IMP) intake. Acceptable methods for women are surgical intervention (e.g. bilateral tubal occlusion), non-hormonal implantable intrauterine device, double-barrier methods, true sexual abstinence (i.e. when this is in line with the preferred and usual lifestyle of the patient) and vasectomised partner (provided that the partner is the sole sexual partner of the patient and the partner has received medical assessment of the surgical success). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), hormonal contraceptives and withdrawal are not acceptable methods of contraception.

    For men: Male patients who are sexually active with a partner of childbearing potential must use, with their partner, a condom plus an approved acceptable contraceptive measure from the time of informed consent until 90 days after the last IMP intake. The following methods are acceptable methods of contraception: partner's use of combined (oestrogen and progestogen-containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal); partner's use of progestogen-only hormonal contraception (oral, injectable/implantable, intrauterine hormone-releasing system); partner's use of implantable intrauterine device; surgical sterilisation (for example, vasectomy or bilateral tubal occlusion).

  14. Previous participation in any other drug investigational study within the past 30 days (or five half-lives of IMP whichever is longer) prior to V1.
  15. Vulnerable patients according to Section 1.61 of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guideline for Good Clinical Practice E6.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    50 mg zamicastat

    50 mg zamicastat once daily

    Drug: Oral zamicastat

  • Experimental
    100 mg zamicastat once daily

    100 mg zamicastat once daily

    Drug: Oral zamicastat

  • Experimental
    150 mg zamicastat once daily

    150 mg zamicastat once daily

    Drug: Oral zamicastat

  • Experimental
    200 mg zamicastat once daily

    200 mg zamicastat once daily

    Drug: Oral zamicastat

Interventions

  • Tablets for oral administration under fed conditions containing 100 mg of zamicastat

    Also known as: BIA 5-1058

06

What researchers measure

Primary outcomes

  1. Area Under the Curve 0-24h (AUC0-24h) (ng.h/mL) - 50 mg

    This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat

    Time frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after investigational medicinal product (IMP) intake)

  2. Area Under the Curve 0-24h (AUC0-24h) (ng.h/mL/mg) - HTD

    This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)

    Time frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake

  3. Maximum Plasma Concentration (Cmax) (ng/mL) - 50 mg

    This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat

    Time frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)

  4. Maximum Plasma Concentration (Cmax) (ng/mL/mg) - HTD

    This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)

    Time frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake

  5. Time Until Cmax (Tmax) (h) - 50 mg

    This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat

    Time frame: Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)

  6. Time Until Cmax (Tmax) (h) - HTD

    This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)

    Time frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake

  7. Minimum Plasma Concentration at the End of the Dosing Interval (Cmin,SS) (ng/mL/mg) - HTD

    This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD). Following multiple administrations of the HTD of zamicastat to PAH patients at MPV3, PK concentrations and parameter summaries for only the 50 mg, 100 mg and 200 mg dose levels are presented and discussed, as the only subject receiving the 150 mg HTD level had a major protocol deviation documented, impacting the reliability of their PK data.

    Time frame: 1, 2, 4, 8, 16 and 24 hours after IMP intake

07

Results

Posted Oct 15, 2024

Participant flow

50 mg Toleration Period - Dose A
Participant flow — 50 mg Toleration Period - Dose A
Milestone50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Started29000
Completed27000
Not completed2000
100 mg Toleration Period - Dose B
Participant flow — 100 mg Toleration Period - Dose B
Milestone50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Started02700
Completed02100
Not completed0600
150 mg Toleration Period - Dose C
Participant flow — 150 mg Toleration Period - Dose C
Milestone50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Started00210
Completed00190
Not completed0020
200 mg Toleration Period - Dose D
Participant flow — 200 mg Toleration Period - Dose D
Milestone50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Started00019
Completed00019
Not completed0000

Outcome measures

PrimaryArea Under the Curve 0-24h (AUC0-24h) (ng.h/mL) - 50 mg

This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat

Time frame:
Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after investigational medicinal product (IMP) intake)
Reported as:
Geometric mean · ng.h/mL
Area Under the Curve 0-24h (AUC0-24h) (ng.h/mL) - 50 mg
ng.h/mL50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Zamicastat155761 ± 44.6—1570 ± 59.7
BIA 5-453_1—172—305 ± 38.5
BIA 5-453_2—181—305 ± 38.5
BIA 5-961—150,187 ± 0—277 ± 94.3
PrimaryArea Under the Curve 0-24h (AUC0-24h) (ng.h/mL/mg) - HTD

This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)

Time frame:
1, 2, 4, 8, 16 and 24 hours after IMP intake
Reported as:
Geometric mean · ng.h/mL/mg
Area Under the Curve 0-24h (AUC0-24h) (ng.h/mL/mg) - HTD
ng.h/mL/mg50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Zamicastat3.097.61 ± 44.6—7.87 ± 59.7
BIA 5-453_1—1.72 ± 0—1.53 ± 38.5
BIA 5-453_2—1.81—1.53 ± 38.5
BIA 5-961_1—1.50—1.39 ± 94.3
BIA 5-961_2—1.87—1.39 ± 94.3
PrimaryMaximum Plasma Concentration (Cmax) (ng/mL) - 50 mg

This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat

Time frame:
Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) (ng/mL) - 50 mg
ng/mL50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Zamicastat13.362.6 ± 60.5—134 ± 94.0
5-453—8.39 ± 33.1—18.8 ± 48.1
BIA 5-961_15.3911.0—17.6 ± 78.2
BIA 5-961_25.3923.9—17.6 ± 78.2
PrimaryMaximum Plasma Concentration (Cmax) (ng/mL/mg) - HTD

This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)

Time frame:
1, 2, 4, 8, 16 and 24 hours after IMP intake
Reported as:
Geometric mean · ng/mL/mg
Maximum Plasma Concentration (Cmax) (ng/mL/mg) - HTD
ng/mL/mg50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Zamicastat0.270.626 ± 60.5—0.672 ± 94.0
BIA 5-453—0.0839 ± 33.1—0.0939 ± 48.1
BIA 5-961_10.1080.110—0.0882 ± 78.2
BIA 5-961_20.1080.239—0.0882 ± 78.2
PrimaryTime Until Cmax (Tmax) (h) - 50 mg

This PK parameters (24-hour profile) for zamicastat and its metabolites will be derived after a single dose of 50 mg zamicastat

Time frame:
Day 1 (0 hours and then 1, 2, 4, 8, 16 and 24 hours after IMP intake)
Reported as:
Geometric mean · h
Time Until Cmax (Tmax) (h) - 50 mg
h50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Zamicastat2.003.00 ± 1.00—4.00 ± 1.00
BIA 5-453—3.00 ± 2.00—4.05 ± 2.00
BIA 5-9614.032.00—8.00 ± 4.00
PrimaryTime Until Cmax (Tmax) (h) - HTD

This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD)

Time frame:
1, 2, 4, 8, 16 and 24 hours after IMP intake
Reported as:
Geometric mean · h
Time Until Cmax (Tmax) (h) - HTD
h50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Zamicastat2.003.00 ± 4.08—4.00 ± 24.00
BIA 5-453—3.00 ± 8.08—4.05 ± 24.0
BIA 5-9614.038.08—8.00 ± 24.0
PrimaryMinimum Plasma Concentration at the End of the Dosing Interval (Cmin,SS) (ng/mL/mg) - HTD

This PK parameter (24-hour profile) for zamicastat and its metabolites will be derived at steady-state at the individual highest tolerated dose (HTD). Following multiple administrations of the HTD of zamicastat to PAH patients at MPV3, PK concentrations and parameter summaries for only the 50 mg, 100 mg and 200 mg dose levels are presented and discussed, as the only subject receiving the 150 mg HTD level had a major protocol deviation documented, impacting the reliability of their PK data.

Time frame:
1, 2, 4, 8, 16 and 24 hours after IMP intake
Reported as:
Geometric mean · ng/mL/mg
Minimum Plasma Concentration at the End of the Dosing Interval (Cmin,SS) (ng/mL/mg) - HTD
ng/mL/mg50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Zamicastat—0.186 ± 36.7—0.198 ± 74.1
BIA 5-453_1—0.0564—0.0479 ± 48.5
BIA 5-453_2—0.0603—0.0479 ± 48.5
BIA 5-961—0.0896—0.0503 ± 58.6

Adverse events

Collected over 94,5 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50 mg Zamicastat0/29 (0%)0/29 (0%)10/29 (34.5%)
100 mg Zamicastat Once Daily0/28 (0%)2/28 (7.1%)15/28 (53.6%)
150 mg Zamicastat Once Daily0/27 (0%)0/27 (0%)15/27 (55.6%)
200 mg Zamicastat Once Daily0/21 (0%)0/21 (0%)11/21 (52.4%)
Most frequent serious events
Most frequent serious events
Event50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Device breakageProduct Issues0/291/280/270/21
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders0/291/280/270/21
Most frequent other events
Showing 10 of 64
Most frequent other events
Event50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once Daily
Sinus arrhythmiaCardiac disorders0/291/282/271/21
NauseaGastrointestinal disorders0/290/282/271/21
FatigueGeneral disorders1/291/282/271/21
Ventricular extrasystolesCardiac disorders0/292/280/270/21
NasopharyngitisInfections and infestations1/292/280/270/21
DizzinessNervous system disorders0/292/280/270/21
InsomniaPsychiatric disorders0/292/280/271/21
HeadacheNervous system disorders2/291/281/270/21
SyncopeNervous system disorders0/291/281/271/21
Gastrointestinal infectionInfections and infestations0/290/280/271/21

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once DailyTotal
<=18 years00000
Between 18 and 65 years1621625
>=65 years00033
Sex: Female, Male
Sex: Female, Male(Participants)50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once DailyTotal
Female1511421
Male01157
Race (NIH/OMB)
Race (NIH/OMB)(Participants)50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once DailyTotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White1621928
More than one race00000
Unknown or Not Reported00000
Height (cm)
Height (cm)(Participants)50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once DailyTotal
<=1.65cm0101213
>1.65152715
Weight (kg)
Weight (kg)(Participants)50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once DailyTotal
<71,5kg0311620
>71,5kg13138
BMI (kg/m2)
BMI (kg/m2)(Participants)50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once DailyTotal
<=25,4kg/m2042915
>=25,5kg/m21201013
Childbearing Potential
Childbearing Potential(Participants)50 mg Zamicastat100 mg Zamicastat Once Daily150 mg Zamicastat Once Daily200 mg Zamicastat Once DailyTotal
Yes041611
No120811
Not Applicable00156
08

Study locations

13 sites
  • Ordensklinikum Linz Elisabethinen, Interne 2 - Kardiologie, Angiologie & Interne Intensivmedizin Fadingerstraße 1
    Linz, 4020, Austria
  • Universitätsklinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Pneumologie Fetscherstraße 74
    Dresden, 01307, Germany
  • Ospedale Generale Regionale Miulli-Cardiologia e UTIC Strada Prov. 127 Acquaviva - Santeramo Km. 4,100
    Acquaviva delle Fonti, 70021, Italy
  • ASST di Monza-Ospedale San Gerardo -Dipartimento di Pneumologia via Pergolesi 33
    Monza, 20900, Italy
  • AOU di Roma-Policlinico Umberto I-Unità Dipartimentale Malattie del Circolo Polmonare Viale del Policlinico 155
    Roma, 00161, Italy
  • Centro Hospitalar Lisboa Norte, E.P.E. - Hospital Pulido Valente Consulta Externa de Hipertensão Pulmonar Alameda das Linhas de Torres, 117
    Lisboa, 1769-001, Portugal
  • Hospital Clinic de Barcelona Calle Villarroel, 170
    Barcelona, 08036, Spain
  • Hospital Universitario "12 de Octubre" Avda. de Córdoba, s/n
    Madrid, 28041, Spain
  • Complejo Asistencial Universitario de Salamanca Pº. San Vicente, 58
    Salamanca, 37007, Spain
  • Hospital Universitario Marques de Valdecilla Avenida Valdecilla, 25
    Santander, 39008, Spain
  • State Institution ""National Scientific Centre "M.D. Strazhesko Institute of Cardiology" of NAMS of Ukraine", Department of symptomatic arterial hypertensions Narodnogo opolcheniya 5
    Kyiv, 03151, Ukraine
  • Golden Jubilee National Hospital Golden Jubilee National Hospital Agamemnon St, Scottish Pulmonary Vascular Unit Golden Jubilee National Hospital
    Clydebank, G81 4DY, United Kingdom
  • Royal Free Hospital Pond Street
    London, NW3 2QG, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Oct 2021, 28 months.

Results were first posted in Oct 2024, 2 years 11 months after primary completion.

Of 28 industry-sponsored phase 2 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's 28 months is close to that.

Counting every sponsor, half of 51 studies reached it within 44 months; a quarter within 26 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2020
First posted
Mar 20, 2020
StartActual
Jun 3, 2019
Primary completionActual
Oct 20, 2021
CompletionActual
Oct 20, 2021
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04316143
Responsible party
Sponsor
First posted
Mar 20, 2020
Start date
Jun 3, 2019
Primary completion
Oct 20, 2021
Completion
Oct 20, 2021
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zamicastat

Start the discussion